JPS5849350A - 免疫調節に影響を与えるペプチド - Google Patents
免疫調節に影響を与えるペプチドInfo
- Publication number
- JPS5849350A JPS5849350A JP57099430A JP9943082A JPS5849350A JP S5849350 A JPS5849350 A JP S5849350A JP 57099430 A JP57099430 A JP 57099430A JP 9943082 A JP9943082 A JP 9943082A JP S5849350 A JPS5849350 A JP S5849350A
- Authority
- JP
- Japan
- Prior art keywords
- arg
- asp
- lye
- val
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 6
- 230000007365 immunoregulation Effects 0.000 title description 3
- 238000000034 method Methods 0.000 claims description 19
- 150000001413 amino acids Chemical group 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 238000005917 acylation reaction Methods 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 230000010933 acylation Effects 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 125000005907 alkyl ester group Chemical group 0.000 claims description 3
- 150000008064 anhydrides Chemical class 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims 2
- 239000004020 conductor Substances 0.000 claims 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 208000033809 Suppuration Diseases 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 210000001747 pupil Anatomy 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 239000000243 solution Substances 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 241001494479 Pecora Species 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- MJINRRBEMOLJAK-DCAQKATOSA-N Arg-Lys-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N MJINRRBEMOLJAK-DCAQKATOSA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 108010003201 RGH 0205 Proteins 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000005265 lung cell Anatomy 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 102100023981 Lamina-associated polypeptide 2, isoform alpha Human genes 0.000 description 3
- 101710163560 Lamina-associated polypeptide 2, isoform alpha Proteins 0.000 description 3
- 101710189385 Lamina-associated polypeptide 2, isoforms beta/gamma Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000000898 Thymopoietin Substances 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002992 thymic effect Effects 0.000 description 3
- 239000000724 thymus hormone Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- -1 pentafluorophenoxy group Chemical group 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010011684 Cutaneous tuberculosis Diseases 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 241000959721 Rosa sempervirens Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 210000002861 immature t-cell Anatomy 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 101150085091 lat-2 gene Proteins 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000009802 regulation of hormone levels Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 108010001055 thymocartin Proteins 0.000 description 1
- 229940034252 thymus extracts Drugs 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/66—Thymopoietins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/18—Thymus derived hormone or factor; related peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU811755A HU185263B (en) | 1981-06-12 | 1981-06-12 | Process for producing peptides effective on the immuncontroll analogous with the tp5 |
| HU1755/81 | 1981-06-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5849350A true JPS5849350A (ja) | 1983-03-23 |
| JPH0357920B2 JPH0357920B2 (cg-RX-API-DMAC7.html) | 1991-09-03 |
Family
ID=10956026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57099430A Granted JPS5849350A (ja) | 1981-06-12 | 1982-06-11 | 免疫調節に影響を与えるペプチド |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4428938A (cg-RX-API-DMAC7.html) |
| EP (1) | EP0067425B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPS5849350A (cg-RX-API-DMAC7.html) |
| AT (1) | AT382625B (cg-RX-API-DMAC7.html) |
| AU (1) | AU551770B2 (cg-RX-API-DMAC7.html) |
| BG (1) | BG60738B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA1241643A (cg-RX-API-DMAC7.html) |
| DE (1) | DE3266354D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK157764C (cg-RX-API-DMAC7.html) |
| HU (1) | HU185263B (cg-RX-API-DMAC7.html) |
| IL (1) | IL66034A (cg-RX-API-DMAC7.html) |
| SU (1) | SU1277903A3 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6221465A (ja) * | 1985-07-18 | 1987-01-29 | Toyota Motor Corp | アルミニウム系母材への２層肉盛方法 |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1164225B (it) * | 1983-05-13 | 1987-04-08 | Anic Spa | Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione |
| US4579840A (en) * | 1983-08-12 | 1986-04-01 | Immunetech Pharmaceuticals | Method of blocking immune complex binding to immunoglobulin Fc receptors |
| US4686282A (en) * | 1983-08-12 | 1987-08-11 | Immunetech, Inc. | Immunotherapeutic polypeptide agents which block immune complex binding to immunoglobulin Fc receptors |
| DE3421614A1 (de) * | 1984-06-09 | 1985-12-12 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von pentapeptiden mit wirkung auf das immunsystem und zwischenprodukte dieses verfahrens |
| US4585757A (en) * | 1984-07-27 | 1986-04-29 | Texas Tech University Health Sciences Center | Hypotensive active peptides |
| JPS61148198A (ja) * | 1984-12-22 | 1986-07-05 | Ajinomoto Co Inc | 新規トリペプチド化合物および甘味剤 |
| FR2591227B1 (fr) * | 1985-12-06 | 1988-11-10 | Pasteur Institut | Peptides capables d'inhiber les interactions entre les virus lav et les lymphocytes t4, produits qui en sont derives et leurs applications |
| IT1188645B (it) * | 1986-04-09 | 1988-01-20 | Ellem Ind Farmaceutica | Tripeptide ad attivita' immunostimolante |
| HUT46044A (en) * | 1986-11-21 | 1988-09-28 | Richter Gedeon Vegyeszet | Process for producing immunstimulant peptides inhibiting multiplication of leukaemic cells and pharmaceutics comprising same |
| HU199878B (en) * | 1987-06-19 | 1990-03-28 | Berlin Chemie Veb | Process for producing acylated splenopentynes and pharmaceutical compositions comprising such compounds as active ingredient |
| US4904802A (en) * | 1987-06-30 | 1990-02-27 | Ajinomoto Co., Inc. | Imides |
| IT1222437B (it) * | 1987-08-04 | 1990-09-05 | Ellem Ind Farmaceutica | Tripeptidi utili come immunostimolanti e nella prevenzione delle metastasi e relativo procedimento di preparazione |
| FR2622587B1 (fr) * | 1987-10-30 | 1990-12-21 | Inst Vaisseaux Sang | Peptide lysyl-arginyl-aspartyl-serine et ses applications en tant que medicament, notamment antithrombotique |
| US5807830A (en) * | 1987-12-30 | 1998-09-15 | Cytoven J.V. | Method for treatment of purulent inflammatory diseases |
| US6136788A (en) * | 1987-12-30 | 2000-10-24 | Cytran, Inc. | Pharmaceutical preparation for the therapy of immune deficiency conditions |
| US5728680A (en) | 1987-12-30 | 1998-03-17 | Cytoven J.V. | Methods for normalizing numbers of lymphocytes |
| US5814611A (en) * | 1988-12-14 | 1998-09-29 | Cytoven J.V. | Pharmaceutical for the therapy of immune deficiency conditions |
| EP0346501B1 (de) * | 1987-12-30 | 1992-07-29 | Vsesojuzny Kardiologichesky Nauchny Tsentr Akademii Meditsinskikh Nauk Sssr | Arzneimittelzubereitung zur behandlung des immunmangels |
| DK15888D0 (da) * | 1988-01-14 | 1988-01-14 | Carlsberg Biotechnology Ltd | Enzymatisk fremgangsmaade til fremstilling af immunmodulerende pentapeptider samt mellemprodukter til brug ved fremgangsmaaden |
| NZ229004A (en) * | 1988-05-19 | 1993-09-27 | Immunobiology Res Inst Inc | Tetrapeptides having t cell helper acitivity |
| HU201095B (en) * | 1988-06-14 | 1990-09-28 | Richter Gedeon Vegyeszet | New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions |
| ES2085865T3 (es) * | 1988-06-30 | 1996-06-16 | Astra Ab | Analogos de dermorfina, sus metodos de preparacion, composiciones farmaceuticas, y metodos de tratamiento terapeutico que los emplean. |
| US5602100A (en) * | 1988-06-30 | 1997-02-11 | Astra Ab | Dermorphin analogs having pharmacological activity |
| US5225400A (en) * | 1988-07-29 | 1993-07-06 | Ellem Industria Farmaceutica S.R.L. | Immunostimulating peptides, a process for their preparation and pharmaceutical compositions containing them |
| US5055296A (en) * | 1988-08-04 | 1991-10-08 | Wagle Sudhakar S | Method of treating chronic fatigue syndrome |
| US5284664A (en) * | 1988-08-04 | 1994-02-08 | Kremers-Urban Company | Method of treating the symptoms of Alzheimer's disease |
| US5316775A (en) * | 1988-08-04 | 1994-05-31 | Kremers-Urban Company | Method of treating hepatitis B infection |
| US5334395A (en) * | 1988-08-04 | 1994-08-02 | Kremers-Urban Company | Method of treating an epstein-barr viral infection |
| US5013546A (en) * | 1988-08-23 | 1991-05-07 | Imreg, Inc. | Methods for modulating antibody production in treating patients with AIDS, ARC and other diseases |
| KR900701298A (ko) * | 1988-09-30 | 1990-12-01 | 원본미기재 | T-세포 억제작용을 보유한 펩티드 |
| US5811399A (en) * | 1988-12-14 | 1998-09-22 | Cytran, Inc. | Pharmaceutical dipeptide compositions and methods of use thereof: immunodepressants |
| US5036050A (en) * | 1989-01-12 | 1991-07-30 | Immunobiology Research Institute, Inc. | Compositions containing thymopentin for topical treatment of skin disorders |
| HU201964B (en) * | 1989-01-13 | 1991-01-28 | Richter Gedeon Vegyeszet | Process for producing peptides inhibiting maturation of t-lymphocytes and activity of macrophages, as well as pharmaceutical compositions comprising same |
| DD296084A5 (de) * | 1989-07-27 | 1991-11-21 | Adw | Verfahren zur herstellung von humanen spleninderivaten |
| US5770576A (en) * | 1989-08-30 | 1998-06-23 | Cytran, Inc. | Pharmaceutical dipeptide compositions and methods of use thereof: systemic toxicity |
| IT1237474B (it) * | 1989-10-05 | 1993-06-07 | Polifarma Spa | Composti tripeptidici e loro uso farmaceutico come immuno-modulatori |
| HU205952B (en) * | 1990-08-23 | 1992-07-28 | Richter Gedeon Vegyeszet | Process for producing cristalline h-arg-lys-asp-oh and h-arg-lys-asp-val-oh and pharmaceutically active compositions containing them |
| IT1244548B (it) * | 1991-02-06 | 1994-07-15 | Poli Ind Chimica Spa | Derivati della 5-oxo-l-prolina e loro applicazioni farmaceutiche |
| US6100380A (en) * | 1991-10-28 | 2000-08-08 | Cytran, Inc. | Immunomodulating peptides and methods of use |
| US6066622A (en) | 1991-10-28 | 2000-05-23 | Cytran, Inc. | Immunomodulating peptides and methods of use |
| US5585359A (en) * | 1994-09-29 | 1996-12-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| RU2107691C1 (ru) * | 1995-03-02 | 1998-03-27 | Дейгин Владислав Исакович | Пептид и способ его получения |
| US6159940A (en) * | 1996-02-28 | 2000-12-12 | Immunotech Developments Inc. | Method for modulating hemopoiesis |
| DE59710628D1 (de) | 1996-08-12 | 2003-09-25 | Mgb Endoskopische Geraete Gmbh | Starres endoskop mit beleuchtung |
| US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
| US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| FI20012082A0 (fi) | 2001-10-26 | 2001-10-26 | Paeivi Liesi | Biologisesti aktiiviset peptidit hermovauroiden korjaamiseksi |
| RU2208442C1 (ru) * | 2002-04-22 | 2003-07-20 | Восточно-Сибирский государственный технологический университет | Комплексное иммунокорригирующее средство |
| WO2003104220A1 (en) * | 2002-06-11 | 2003-12-18 | Bristol-Myers Squibb Company | Asymetric synthesis of amino-pyrrolidinones |
| US20060205669A1 (en) * | 2004-09-16 | 2006-09-14 | The Regents Of The University Of California | G-type peptides and other agents to ameliorate atherosclerosis and other pathologies |
| JP2008522980A (ja) | 2004-12-06 | 2008-07-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 小血管の構造および機能を改善するための方法 |
| US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| KR20080007491A (ko) * | 2005-04-29 | 2008-01-21 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 염증성 반응을 특징으로 하는 병리를 치료하기 위한 펩티드및 펩티드 모방체 |
| RU2301074C1 (ru) * | 2006-05-30 | 2007-06-20 | Общество С Ограниченной Ответственностью "Сиа Пептайдс" | Пептид, обладающий иммуногеропротекторным действием, фармацевтическая композиция на его основе и способ ее применения |
| CA2697957A1 (en) | 2007-08-28 | 2009-03-12 | Uab Research Foundation | Synthetic apolipoprotein e mimicking polypeptides and methods of use |
| CA2704729C (en) * | 2007-08-28 | 2020-06-23 | Uab Research Foundation | Synthetic apolipoprotein e mimicking polypeptides and methods of use |
| US10653747B2 (en) | 2014-07-31 | 2020-05-19 | Uab Research Foundation | ApoE mimetic peptides and higher potency to clear plasma cholesterol |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4190646A (en) | 1975-11-11 | 1980-02-26 | Sloan-Kettering Institute For Cancer Research | Polypeptide compositions and methods |
| GB1565032A (en) * | 1978-01-27 | 1980-04-16 | Sloan Kettering Inst Cancer | Polypeptide compositions and methods for their manufacture |
| US4261886A (en) | 1980-03-13 | 1981-04-14 | Ortho Pharmaceutical Corporation | Peptides having thymopoietin-like activity |
| CA1157466A (en) * | 1979-04-12 | 1983-11-22 | Gideon Goldstein | Peptides having thymopoietin-like activity |
| DE2938420A1 (de) * | 1979-09-22 | 1981-04-09 | Hoechst Ag, 6000 Frankfurt | Neue peptide und verfahren zu ihrer herstellung |
-
1981
- 1981-06-12 HU HU811755A patent/HU185263B/hu not_active IP Right Cessation
-
1982
- 1982-06-11 EP EP82105097A patent/EP0067425B1/de not_active Expired
- 1982-06-11 IL IL66034A patent/IL66034A/xx not_active IP Right Cessation
- 1982-06-11 DK DK264782A patent/DK157764C/da not_active IP Right Cessation
- 1982-06-11 JP JP57099430A patent/JPS5849350A/ja active Granted
- 1982-06-11 US US06/387,655 patent/US4428938A/en not_active Expired - Lifetime
- 1982-06-11 CA CA000405011A patent/CA1241643A/en not_active Expired
- 1982-06-11 AT AT0227082A patent/AT382625B/de not_active IP Right Cessation
- 1982-06-11 DE DE8282105097T patent/DE3266354D1/de not_active Expired
- 1982-06-11 SU SU823454444A patent/SU1277903A3/ru active
- 1982-06-11 AU AU84799/82A patent/AU551770B2/en not_active Ceased
-
1993
- 1993-12-02 BG BG098260A patent/BG60738B2/bg unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6221465A (ja) * | 1985-07-18 | 1987-01-29 | Toyota Motor Corp | アルミニウム系母材への２層肉盛方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| DK264782A (da) | 1982-12-13 |
| SU1277903A3 (ru) | 1986-12-15 |
| EP0067425B1 (de) | 1985-09-18 |
| CA1241643A (en) | 1988-09-06 |
| ATA227082A (de) | 1986-08-15 |
| HU185263B (en) | 1984-12-28 |
| IL66034A0 (en) | 1982-09-30 |
| EP0067425A1 (de) | 1982-12-22 |
| BG60738B2 (bg) | 1996-01-31 |
| DK157764B (da) | 1990-02-12 |
| IL66034A (en) | 1985-09-29 |
| AT382625B (de) | 1987-03-25 |
| JPH0357920B2 (cg-RX-API-DMAC7.html) | 1991-09-03 |
| DE3266354D1 (en) | 1985-10-24 |
| DK157764C (da) | 1990-07-09 |
| AU8479982A (en) | 1982-12-16 |
| AU551770B2 (en) | 1986-05-08 |
| US4428938A (en) | 1984-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS5849350A (ja) | 免疫調節に影響を与えるペプチド | |
| US3904594A (en) | Somatostatin and acylated des-(ala' 1', gly' 2') derivatives thereof | |
| EP0078228B1 (en) | Novel peptide compounds, a process for manufacturing them, pharmaceutical compositions containing them, and methods for treating ulcer and thrombus with them | |
| JPH03504013A (ja) | Ｔ細胞ヘルパー活性を有するペプチド | |
| FR2526791A1 (fr) | Nouveaux peptides utiles notamment comme medicaments immunopotentiateurs | |
| US3842064A (en) | Psychopharmacologically active tetra-,penta-,hexa-,and hepta-peptides | |
| JP2625156B2 (ja) | 細胞接着活性コア配列の繰り返し構造からなるポリペプチド | |
| JPS61218598A (ja) | バ−ソポイエチン | |
| JPS63250360A (ja) | サイモペンチンレトロ−インバーソ類似体及びそのフラグメント | |
| US5079231A (en) | Immunostimulating peptides, a process for their preparation and pharmaceutical compositions containing them | |
| US5008246A (en) | Novel peptides suppressing the function of the immune system, pharmaceutical compositions containing them and process for preparing same | |
| US3749703A (en) | Asn15-bovine thyrocalcitonin | |
| Deber et al. | Cyclic Peptides VII. The Synthesis and Characterization of Cyclic Peptides with Repeating Pro‐Gly Sequences | |
| JPS60226898A (ja) | 新規ゴナドリベリン誘導体およびその製造方法 | |
| JPS642600B2 (cg-RX-API-DMAC7.html) | ||
| JPS62169730A (ja) | トリプトフアンを含有するオリゴペプチドを用いる神経障害の治療方法 | |
| JPH09503200A (ja) | Ｃ反応性タンパク質断片から誘導されたオリゴペプチド | |
| JPH0796557B2 (ja) | 新規ペプチド、その製法およびそれを含有する医薬組成物 | |
| US5118669A (en) | Peptides and intermediates therefor useful as antiallergic agents, vasodilators and immunoregulators | |
| JPH0631314B2 (ja) | 新規なゴナドリベリン誘導体 | |
| GB2185486A (en) | Conjugate of alpha-melanotropin with p-L-sarcolysine (melphalan) | |
| US3814746A (en) | Mannich base of tetracycline and polypeptides | |
| JP2918746B2 (ja) | ペプチド誘導体およびその用途 | |
| AU623148B2 (en) | Probursin | |
| JPH0645637B2 (ja) | 免疫促進活性を有するトリペプチド |